Evidence map›Paper›PMID 35479943›Full record

ArticleFrontiers in medicine2022

Jie Zhu, Zhicheng Wang, Lu Tao, Ling Han, Qiong Huang, Xu Fang, Ke Yang, Guiqin Huang, Zhizhong Zheng, Nikhil Yawalkar and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Biomedicines · 2023
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Jie ZhuShanghai Institute of Dermatology, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Zhicheng WangDepartment of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Lu TaoShanghai Institute of Dermatology, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Ling HanShanghai Institute of Dermatology, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Qiong HuangShanghai Institute of Dermatology, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Xu FangShanghai Institute of Dermatology, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Ke YangDepartment of Information, Huashan Hospital, Fudan University, Shanghai, China.
Guiqin HuangShanghai Institute of Dermatology, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Zhizhong ZhengShanghai Institute of Dermatology, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Nikhil YawalkarDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Zhenghua ZhangShanghai Institute of Dermatology, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Kexiang YanShanghai Institute of Dermatology, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Fudan University · CNHuashan Hospital · CNUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: To assess whether Methods: This prospective, single-arm, interventional study recruited a total of 309 patients with psoriasis, 163 with psoriatic arthritis and 146 without psoriatic arthritis, who completed a 12-week MTX treatment and 1,031 healthy controls. Patients' characteristics including age, gender, disease duration, height, weight, smoking status, alcohol consumption, medical history, disease severity and liver function test results were accessed and recorded. Single nucleotide polymorphism (SNP) genotyping of rs1801131 and rs1801133 in the Results: The rs1801133 CC genotype was more frequent in patients with PsA than those with PsO and healthy controls (42.3% vs. 28.8% vs. 33.1%, Conclusions: This study provided some evidence for

Indexed as

biomarkermethotrexatemethylenetetrahydrofolate reductasepharmacogeneticspsoriasispsoriatic arthritis

Identifiers

PMID35479943
PMCPMC9035632
OpenAlexW4223411743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.